Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporin A vs Mini-Monoka Stent for Acquired Punctal Stenosis
NCT05771012Completed
- Sponsor
- Farwaniya Hospital
- Start
- Jan 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cyclosporine 2% ophthalmic solution in acquired punctal stenosis (APS) (2 arms), sponsored by Farwaniya Hospital. Primary endpoints: Functional success rate at 6 months and Anatomical success rate at 6 months. Started Jan 2021; status: completed.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
acquired punctal stenosis (APS)
Beyond the preview
Go deeper on NCT05771012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05771012.